InFlectis BioScience-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:InFlectis BioScience - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014141
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
InFlectis BioScience (InFlectis) is a drug discovery company that discovers and develops small molecule drugs that target the unfolded protein response (UPR) to treat misfolding protein disorders such as age-related and neurodegenerative diseases. The company’s product lead candidate IFB-088, modulates the UPR through protein-protein interaction and targets neurodegenerative and orphan diseases such as charcot-marie-tooth and retinitis pigmentosa. InFlectis has collaboration with European organization for Rare Diseases (EURORDIS) and Atlanpole for operational and customized support. The company intends to develop other several drug candidates to treat other age related diseases such as Alzheimer’s Parkinson’s, type II Diabetes and some forms of cancer. InFlectis is headquartered in Nantes, France.

InFlectis BioScience – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
InFlectis BioScience, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
InFlectis BioScience, Medical Devices Deals, 2011 to YTD 2017 9
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
InFlectis BioScience, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
InFlectis BioScience Raises USD5 Million in Series A Financing 11
InFlectis BioScience Raises USD2 Million in Seed Financing Round 12
InFlectis BioScience Raises USD1.21 Million in Venture Financing 13
Partnerships 14
InFlectis BioScience Enters into Licensing Agreement with Valneva 14
InFlectis BioScience – Key Competitors 15
InFlectis BioScience – Key Employees 16
InFlectis BioScience – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product Approvals 18
Jan 25, 2016: IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
InFlectis BioScience, Pharmaceuticals & Healthcare, Key Facts 2
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
InFlectis BioScience, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
InFlectis BioScience, Deals By Therapy Area, 2011 to YTD 2017 8
InFlectis BioScience, Medical Devices Deals, 2011 to YTD 2017 9
InFlectis BioScience, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
InFlectis BioScience Raises USD5 Million in Series A Financing 11
InFlectis BioScience Raises USD2 Million in Seed Financing Round 12
InFlectis BioScience Raises USD1.21 Million in Venture Financing 13
InFlectis BioScience Enters into Licensing Agreement with Valneva 14
InFlectis BioScience, Key Competitors 15
InFlectis BioScience, Key Employees 16

★海外企業調査レポート[InFlectis BioScience-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Manhattan Associates Inc (MANH):企業の財務・戦略的SWOT分析
    Manhattan Associates Inc (MANH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • PJSC MegaFon:企業のM&A・事業提携・投資動向
    PJSC MegaFon - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PJSC MegaFon Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Maruti Suzuki India Ltd (MARUTI):企業の財務・戦略的SWOT分析
    Maruti Suzuki India Ltd (MARUTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Strand Life Sciences Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Strand Life Sciences Pvt Ltd (Strand Life) is a healthcare technology company that develops offers bioinformatics and clinical diagnostic software products. The company offers bioinformatics software for most analytics platforms such as microarrays, mass spectrometry, next generation sequenc …
  • Standard Life plc:企業のM&A・事業提携・投資動向
    Standard Life plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Standard Life plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Tarveda Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tarveda Therapeutics Inc (Tarveda), formerly Blend Therapeutics Inc is a clinical stage biopharmaceutical company that discovers and develops miniaturized novel biologic drug conjugates. The company develops targeted anti-cancer medicines for advancing the treatment for solid tumors. Its pip …
  • Indeck Energy Services Inc:発電所・企業SWOT分析
    Indeck Energy Services Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular Therapeutix), formerly I-Therapeutix Inc, is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammatio …
  • Berry Global Group, Inc.:企業の戦略・SWOT・財務情報
    Berry Global Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Berry Global Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Celgene Corp (CELG):製薬・医療:M&Aディール及び事業提携情報
    Summary Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaz …
  • American Bio Medica Corp (ABMC):企業の製品パイプライン分析2018
    Summary American Bio Medica Corp (ABMC) is a biotechnology company that develops, manufactures and markets immunoassay test kits. The company’s products include Rapid TOX, a point of collection testing product that detects 1-10 drugs of abuse in a urine specimen; Rapid One, a test cassette which is …
  • Sarepta Therapeutics Inc (SRPT):企業の財務・戦略的SWOT分析
    Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Edge Therapeutics Inc (EDGE):企業の財務・戦略的SWOT分析
    Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neuro …
  • Itausa – Investimentos Itau S.A.:企業の戦略・SWOT・財務情報
    Itausa - Investimentos Itau S.A. - Strategy, SWOT and Corporate Finance Report Summary Itausa - Investimentos Itau S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Achillion Pharmaceuticals Inc (ACHN):製薬・医療:M&Aディール及び事業提携情報
    Summary Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients …
  • Insightra Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Insightra Medical Inc (Insightra Medical), a subsidiary of GPB Life Science Holdings LLC is a medical device company that develops disposable devices. The company provides cardiovascular and surgical solutions. It offers cardiovascular solutions such as Ultra 7FR IAB and modulare. The Modula …
  • Booking Holdings Inc:企業の戦略・SWOT・財務分析
    Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ovid Therapeutics Inc (OVID):製薬・医療:M&Aディール及び事業提携情報
    Summary Ovid Therapeutics Inc (Ovid Therapeutics) is a bio-pharmaceutical company which identifies, discovers, and develops medicines for neurological disorders. The company’s pipeline products are indicated for diseases such as Angelman Syndrome and Fragile X Syndrome. It develops, assess, commerci …
  • LifeArc:企業のM&A・事業提携・投資動向
    LifeArc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LifeArc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Annaly Capital Management Inc:戦略・SWOT・企業財務分析
    Annaly Capital Management Inc - Strategy, SWOT and Corporate Finance Report Summary Annaly Capital Management Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆